BridgeBio Pharma
BBIO
BBIO
161 hedge funds and large institutions have $8.37B invested in BridgeBio Pharma in 2020 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 37 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
161
Holders Change
+32
Holders Change %
+24.81%
% of All Funds
2.86%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.21%
New
43
Increased
64
Reduced
37
Closed
11
Calls
$27.7M
Puts
$8.42M
Net Calls
+$19.3M
Net Calls Change
+$18.2M
Top Buyers
| 1 |
Rockefeller Capital Management
New York
|
+$55.3M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$38.7M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32.7M |
| 4 |
BlackRock
New York
|
+$28.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.5M |
Top Sellers
| 1 |
Citigroup
New York
|
-$13.2M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8.75M |
| 3 |
AG
Artal Group
Luxembourg
|
-$7.11M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$4.94M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.12M |
